It is converted to aciclovir in the body after absorption.In 2009, acyclovir in combination with hydrocortisone cream, marketed as Xerese, was approved in the United States for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (six years of age and older). Society and culture
Names
Aciclovir is the international nonproprietary name (INN) and British Approved Name (BAN) while acyclovir is the United States Adopted Name (USAN) and former British Approved Name.It was originally marketed as Zovirax; patents expired in the 1990s and since then it is generic and is marketed under many brand names worldwide. Notes
References
Further reading
Hazra, S; Konrad, M; Lavie, A (2010). "The sugar ring of the nucleoside is required for productive substrate positioning in the active site of human deoxycytidine kinase (dCK): Implications for the development of dCK-activated acyclic guanine analogues". Journal of Medicinal Chemistry. 53 (15): 5792–800. doi:10.1021/jm1005379. PMC 2936711. PMID 20684612. Harvey Stewart C. in Remingtons Pharmaceutical Sciences 18th edition: (ed. Gennard, Alfonso R.)  Mack Publishing Company, 1990. ISBN 0-912734-04-3. Huovinen P., Valtonen V. in Kliininen Farmakologia (ed. Neuvonen et al.). Kandidaattikustannus Oy, 1994. ISBN 951-8951-09-8. Périgaud C.; Gosselin G.; Imbach J.-L. (1992). "Nucleoside analogues as chemotherapeutic agents: a review". Nucleosides and Nucleotides. 11 (2–4): 903–945. doi:10.1080/07328319208021748. Rang H.P., Dale M.M., Ritter J.M. : Pharmacology, 3rd edition. Pearson Professional Ltd, 1995. 2003 (5th) edition ISBN 0-443-07145-4; 2001 (4th) edition ISBN 0-443-06574-8; 1990 edition ISBN 0-443-03407-9. External links
"Acyclovir". Drug Information Portal.
Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist.Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was approved for medical use in the United States in October 2019. In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries. Medical uses
In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older. Society and culture
Legal status
Trifarotene was approved for medical use in the United States in October 2019, in Canada in November 2019, and in Australia in January 2021. References
External links
"Trifarotene". Drug Information Portal. U.S. National Library of Medicine (NLM).